말초동맥질환 시장 규모, 점유율, 동향 및 예측 : 유형별, 최종사용자별, 지역별(2026-2034년)

The global peripheral artery disease market size was valued at USD 5.1 Billion in 2025. The market is projected to reach USD 7.9 Billion by 2034, exhibiting a CAGR of 4.78% from 2026-2034. North America currently dominates the market, holding a market share of 39.1% in 2025. At present, rising geriatric population, various technological innovations in the diagnosis and treatment, increasing adoption of home care settings, and improvements in healthcare infrastructure are propelling the market growth. Besides this, changing living standards of individuals are contributing to the expansion of the peripheral artery disease market share.

At present, the market is growing because of the increasing prevalence of chronic health ailments, including diabetes, and high cholesterol, which greatly elevate the risk of peripheral artery disease. An increasing elderly demographic is also fueling the market expansion, since senior individuals are more susceptible to circulatory issues. High awareness among patients and healthcare providers is resulting in prompt diagnosis and timely therapy. In addition, innovations in diagnostic imaging and minimally invasive techniques enhance treatment results and motivate more patients to pursue care. The development of novel medication treatments is further enhancing disease management and symptom regulation. Rising healthcare spending and enhanced access to medical services in both urban and rural areas are strengthening the peripheral artery disease market growth.

The United States has emerged as a major region in the peripheral artery disease market owing to many factors. The market is growing steadily due to the high prevalence of lifestyle-related diseases like diabetes, obesity, high blood pressure, and smoking, significantly contributing to the development of peripheral artery disease. As per the US Centers for Disease Control and Prevention (CDC), the percentage of obesity among adults in the US rose by 13.6% from 2010 to 2024. An aging population is increasing the number of individuals susceptible to vascular conditions, further driving the demand. The country has a strong healthcare infrastructure that supports early diagnosis, advanced imaging, and minimally invasive treatment options. Continuous advancements in drug development and medical devices improve treatment outcomes and reduce complications.

PERIPHERAL ARTERY DISEASE MARKET TRENDS:

Technological Advancements in Minimally Invasive Surgeries

The development of sophisticated catheter-based devices and techniques is revolutionizing vascular interventions, offering less invasive alternatives to traditional open surgeries. These advancements are significantly improving treatment outcomes by reducing patient discomfort, shortening hospital stays, and enabling faster recovery times. New devices, such as advanced angioplasty balloons, drug-coated balloons, atherectomy devices, and specialized stents, are expanding the range of treatment options available for peripheral artery disease. These innovations offer greater flexibility, deliverability, and efficacy, allowing clinicians to treat complex lesions more effectively. Furthermore, these less invasive procedures preserve normal vascular anatomy while improving long-term patency rates, leading to better overall outcomes. The peripheral artery disease market trends are showing a shift towards more advanced, patient-friendly treatment options, with increasing demand for innovative devices that enable better clinical results and improved quality of life for peripheral artery disease patients. The American College of Cardiology estimated that peripheral artery disease impacted over 200 Million individuals globally, affecting 10%-15% of adults aged over 50, as of October 2024.

Changing Living Standards of Individuals

People are suffering from peripheral artery disease due to lifestyle-related factors, such as diabetes, obesity, hypertension, and smoking. As worldwide rates of these conditions are increasing, particularly in regions with aging populations, more individuals are at risk of peripheral artery disease. Studies indicated that in 2024, people with diabetes were 3 to 4 times more prone to developing peripheral artery disease. Rising rates of obesity, hypertension, and smoking contributed to the number of affected individuals. Diabetes leads to atherosclerosis, which narrows arteries and restricts blood flow, leading to peripheral artery disease. As a result, the demand for diagnostic tools and treatments, such as angioplasty, stenting, and bypass surgery, is growing.

Increasing Aging Population

Rising aging population across the globe is offering a favorable peripheral artery disease market outlook. Older adults are facing a higher risk of developing peripheral artery disease owing to age-related vascular changes and atherosclerosis. As per industry reports, the worldwide population of individuals aged 60 and above is set to hit 1.4 Billion by 2030, and older adults are particularly susceptible to age-related atherosclerotic changes that narrow or block peripheral arteries. As people age, their arteries naturally lose elasticity, which can result in narrowed or blocked arteries, a hallmark of peripheral artery disease. This demographic shift is driving the demand for healthcare services, including diagnostics, preventive treatments, and minimally invasive interventions like angioplasty and stent placement. In line with this, healthcare providers are focusing on addressing the needs of elderly patients, who often have complex health profiles, thereby contributing to the market growth.

PERIPHERAL ARTERY DISEASE INDUSTRY SEGMENTATION:

Analysis by Type:

• Peripheral Angioplasty Balloons
• Peripheral Stents
• Peripheral Catheters
• Inferior Vena Cava (IVC) Filters
• Plaque Modification Devices
• Hemodynamic Flow Alteration Devices
• Peripheral Accessories

Peripheral stents held 22.8% of the market share in 2025. They offer an effective, minimally invasive solution for restoring blood flow in narrowed or blocked peripheral arteries. These stents are widely used to treat conditions, such as claudication and critical limb ischemia, which are common complications of peripheral artery disease. Peripheral stents help prevent artery collapse after angioplasty by keeping the blood vessels open, improving circulation and reducing symptoms like pain and fatigue. Their use results in quicker recovery times, lower risk of complications, and fewer repeat procedures compared to traditional surgical interventions. Technological advancements, such as drug-eluting stents and bioresorbable materials, are further enhancing their performance and expanding their adoption among physicians. As per the peripheral artery disease market forecast, the growing preferences for non-surgical treatments will continue to drive the demand for stents.

Analysis by End User:

• Hospitals
• Specialty Clinics
• Others

Hospitals hold a significant share in the market based on end user because they offer comprehensive diagnostic and treatment facilities under one roof. Patients with peripheral artery disease often require advanced imaging, surgical interventions, and continuous monitoring, which hospitals are well-equipped to provide. Hospitals also have specialized vascular departments, experienced medical professionals, and access to the latest technologies. Emergency care and complex procedures, such as stent placements and bypass surgeries, are usually handled in hospitals.

Specialty clinics focus on outpatient care, early diagnosis, and minimally invasive treatments. These clinics often offer faster services, shorter wait times, and personalized care compared to large hospital settings. Patients with milder symptoms or those requiring routine follow-ups prefer specialty clinics for convenience. They are also equipped with modern diagnostic tools and employ vascular specialists who manage peripheral artery disease with targeted therapies.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America, accounting for a share of 39.1%, enjoys the leading position in the market. The region is experiencing high prevalence of lifestyle-related diseases, such as diabetes and smoking, which is contributing to the development of peripheral artery disease. The region has a well-established healthcare infrastructure that supports early diagnosis, advanced treatment options, and widespread access to care. There is also strong awareness among patients and healthcare providers about the symptoms and long-term complications of peripheral artery disease, leading to timely medical intervention. Continuous advancements in medical technologies, including imaging systems, drug therapies, and minimally invasive procedures, are further driving treatment adoption. In addition, high expenditure on research and development (R&D) activities by key industry players is leading to the creation of innovative solutions. Supportive reimbursement policies and government health programs are also encouraging routine screenings and preventive care. With a large patient population, expansion of hospitals, and access to cutting-edge treatments, North America continues to dominate the market in both value and innovation. As per the American Hospital Association, the United States had 6,093 hospitals in the beginning of 2025.

KEY REGIONAL TAKEAWAYS:

UNITED STATES PERIPHERAL ARTERY DISEASE MARKET ANALYSIS

The United States peripheral artery disease market holds a share of 89.10% in the North American region. It is expanding due to a significant rise in lifestyle-related conditions, such as obesity and high cholesterol. Increased government focus on early cardiovascular screening programs is also fostering early diagnosis, leading to timely interventions. According to the CDC, as of October 2024, six out of every ten Americans suffered from a chronic illness, while four out of ten faced two or more, highlighting the significant need for vascular treatment. Furthermore, the integration of artificial intelligence (AI) into vascular imaging and diagnostic platforms is enhancing clinical outcomes and decision-making precision. Technological innovations in minimally invasive endovascular therapies are being favored by healthcare providers and patients, accelerating procedural volume. The growing utilization of wearable health monitoring devices is further supporting continuous patient tracking and preventative care strategies. Additionally, heightened awareness about peripheral vascular health through national health initiatives and collaborations with healthcare professionals is strengthening the market landscape. Investment in outpatient care facilities that offer vascular services is also on the rise, providing more accessible care. With a robust infrastructure supporting clinical research and patient trials, the US continues to be at the forefront of peripheral artery disease therapy development.

EUROPE PERIPHERAL ARTERY DISEASE MARKET ANALYSIS

The Europe peripheral artery disease market is benefiting from an aging population and the growing emphasis on geriatric care services. Increased availability of vascular diagnostic tools in public healthcare systems is improving peripheral artery disease detection at earlier stages. Reports indicate that by 2050, 40.6% of the EU-27 population will be 55 years or older, resulting in a significant number of people at higher risk for peripheral artery disease. A surge in cross-border research collaborations within the European Union is promoting the development of innovative vascular health solutions tailored to diverse populations. Furthermore, clinical adoption of drug-eluting technologies and hybrid revascularization procedures is driving procedural efficiency across hospital settings. The rise of value-based healthcare initiatives is motivating healthcare systems to invest in long-term disease management programs, including peripheral artery disease. Preventative care is being reinforced through mobile health clinics and regional cardiovascular screening events, especially in underserved areas. Additionally, digital therapeutics tailored to vascular rehabilitation are being introduced, facilitating remote patient engagement and follow-up care.

ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET ANALYSIS

The Asia-Pacific peripheral artery disease market is witnessing notable growth due to a surge in urbanization activities and sedentary lifestyles. The expansion of universal health coverage schemes across several nations is driving the demand for standardized peripheral artery disease diagnostics and treatment. As per industry reports, between 2025 and 2050, crude cardiovascular mortality in Asia is set to increase by 91.2%, which is significantly influencing early screening and disease management efforts. There is a strong transition towards capacity-building programs to train healthcare workers in vascular care, which is improving diagnostic accuracy and treatment accessibility. Additionally, regional production of cost-effective stents and catheters is supporting broader adoption of endovascular procedures across tier II and III cities. Mobile telemedicine units and AI-oriented vascular screening tools are gaining traction in remote areas, enhancing patient outreach. These developments are shaping a rapidly evolving and inclusive market landscape across the region.

LATIN AMERICA PERIPHERAL ARTERY DISEASE MARKET ANALYSIS

The Latin American peripheral artery disease market is progressing steadily, supported by expanding public health infrastructure and the growing awareness about vascular health risks. A recent report highlighted that Brazil's funding for its Unified Health System was set to increase by 6.2% relative to 2024, indicating heightened national investments in both preventive and interventional cardiovascular services. Rising participation in international clinical trials is bringing exposure to advanced treatment methodologies and best practices. The growth of private diagnostic centers that offer specialized vascular assessments is contributing to the earlier identification of peripheral artery disease cases. Furthermore, academic partnerships facilitate knowledge exchange and technology transfer, enhancing procedural quality and training. Moreover, regional health campaigns aimed at promoting preventative cardiovascular care are catalyzing the demand for peripheral artery disease-related services.

MIDDLE EAST AND AFRICA PERIPHERAL ARTERY DISEASE MARKET ANALYSIS

The Middle East and Africa peripheral artery disease market is experiencing gradual growth, driven by the ongoing shift towards preventive healthcare practices and increased funding in primary care infrastructure. According to the US-Saudi Business Council, in 2025, 5% of the population in Saudi Arabia will be 60 years old or older, with this number expected to grow notably by 2040, signaling a rising demand for vascular care services. Public health authorities are promoting cardiovascular wellness through community outreach and mobile diagnostic camps. The integration of point-of-care (POC) testing devices in rural clinics is enhancing early peripheral artery disease detection. The growing participation in healthcare technology exhibitions and training forums is encouraging the adoption of digital diagnostic tools. These regional advancements are contributing to a more structured and responsive peripheral artery disease care ecosystem.

COMPETITIVE LANDSCAPE:

Key players are developing advanced treatment options, improving diagnostic technologies, and expanding access to care. They are investing heavily in R&D activities to create innovative medical devices, drug therapies, and minimally invasive procedures that improve patient outcomes and reduce recovery time. These companies are also focusing on generating awareness among healthcare providers and patients through educational campaigns and training programs. By partnering with hospitals, clinics, and research institutions, key players help ensure the latest technologies are effectively used in clinical settings. They also support large-scale clinical trials to prove the safety and effectiveness of new treatments. In addition, their worldwide reach and distribution networks assist in making peripheral artery disease treatments available in both developed and emerging markets. For instance, in March 2025, Lupin released generic rivaroxaban 2.5 mg tablets in the US following the receipt of final FDA approval. The medication, a generic variant of Xarelto, was utilized to lower cardiovascular risks in individuals with peripheral artery disease and coronary artery disease.

The report provides a comprehensive analysis of the competitive landscape in the peripheral artery disease market with detailed profiles of all major companies, including:

• Abbott Laboratories
• AngioDynamics
• B. Braun Melsungen AG
• Becton Dickinson and Company
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Cardinal Health Inc.
• Cook Medical LLC
• Koninklijke Philips N.V.
• Medtronic plc
• Terumo Corporation

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the peripheral artery disease market?

2. What is the future outlook of peripheral artery disease market?

3. What are the key factors driving the peripheral artery disease market?

4. Which region accounts for the largest peripheral artery disease market share?

5. Which are the leading companies in the global peripheral artery disease market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Peripheral Artery Disease Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Peripheral Angioplasty Balloons
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Peripheral Stents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Peripheral Catheters
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Inferior Vena Cava (IVC) Filters
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Plaque Modification Devices
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Hemodynamic Flow Alteration Devices
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Peripheral Accessories
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Specialty Clinics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 AngioDynamics
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 B. Braun Melsungen AG
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 SWOT Analysis
  • 13.3.4 Becton Dickinson and Company
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Biotronik SE & Co. KG
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 SWOT Analysis
  • 13.3.6 Boston Scientific Corporation
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Cardinal Health Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Cook Medical LLC
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 SWOT Analysis
  • 13.3.9 Koninklijke Philips N.V.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Medtronic plc
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Terumo Corporation
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis